Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JimaTong Tablet is a Traditional Chinese Medicine (TCM) candidate developed by Zhejiang University of Traditional Chinese Medicine for the treatment of stage 1 primary hypertension. It is specifically formulated for patients exhibiting the "Liver-Fire Hyperactivity" pattern, a diagnostic category in TCM characterized by symptoms such as dizziness, headache, and irritability. The drug has been evaluated in Phase 2 clinical trials in China to assess its efficacy and safety compared to placebo in lowering blood pressure and improving TCM-related symptoms. As a botanical product, it likely functions through the synergistic effects of multiple active ingredients derived from herbal sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JimaTong Tablet.